CDXC ChromaDex Corporation

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D/A

(Rule 13d-101)

INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a)

AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 9)*

CHROMADEX CORPORATION

(Name of Issuer)

COMMON STOCK, $0,001 PAR VALUE PER SHARE

(Title of Class of Securities)

171077407

(CUSIP Number)

Li Ka Shing

Attention: Pau Yee Wan Ezra

c/o 7/F, Cheung Kong Center

2 Queen’s Road Central

Hong Kong

(852)2128-8888

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 20, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d 1(e), 240.13d 1(f) or 240.13d 1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

EXPLANATORY STATEMENT

This Amendment No. 9 to Schedule 13D (“Amendment No. 9”) relates to the shares of Common Stock of the Issuer (the “Shares”) and is being filed on behalf of the Reporting Person. This Amendment No. 9 amends and supplements Amendment No. 8 to Schedule 13D previously filed with the Securities and Exchange Commission (the “SEC”) on September 7, 2023 (“Amendment No. 8”), Amendment No. 7 to Schedule 13D previously filed with the SEC on October 3, 2022 (“Amendment No. 7”), Amendment No. 6 to Schedule 13D previously filed with the SEC on May 20, 2022 (“Amendment No. 6”), the Amendment No. 5 to Schedule 13D previously filed with the SEC on November 21, 2017 (“Amendment No. 5”), the Amendment No. 4 to Schedule 13D previously filed with the SEC on November 7, 2017 (“Amendment No. 4”), the Amendment No. 3 to Schedule 13D previously filed with the SEC on August 22, 2017 (“Amendment No. 3”). the Amendment No. 2 to Schedule 13D previously filed with the SEC on May 26, 2017 (“Amendment No. 2”). the Amendment No. 1 to Schedule 13D previously filed with the SEC on May 11, 2017 (“Amendment No. 1”), and the initial Schedule 13D previously filed with the SEC on May 8, 2017 (the “Initial Schedule 13D”, together with Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, Amendment No. 8 and this Amendment No. 9, the “Schedule 13D”). The filing of this Amendment No. 9 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.

This Schedule 13D relates to shares of Common Stock of the Issuer. The address of the Issuer’s principal executive office is 10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Item 2 (a)—(c). This Schedule 13D is being filed by the following persons: Li Ka Shing, a permanent resident of the Hong Kong Special Administrative Region, People’s Republic of China (“Li Ka Shing”), Mayspin Management Limited, a British Virgin Islands corporation (“Mayspin”), Prime Tech Global Limited, a British Virgin Islands corporation (“Prime Tech”), Apex Dynasty Limited, a British Virgin Islands corporation (“Apex”), and Alpha Mount International Limited, a British Virgin Islands corporation (“Alpha”). Li Ka Shing, Mayspin, Prime Tech, Apex and Alpha are sometimes referred to herein as a “Reporting Person” and collectively, as the “Reporting Persons.”

Li Ka Shing is the sole shareholder of Mayspin. Mayspin is the sole shareholder of Prime Tech. Li Ka Shing is the sole shareholder of Apex. Apex is the sole shareholder of Alpha.

The principal business of each of the Reporting Persons is investing.

The registered office address of each of Mayspin, Apex, and Alpha is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.

The registered office address of Prime Tech is 2/F, Palm Grove House, P.O. Box 3340, Road Town, Tortola, British Virgin Islands.

The business address of Li Ka Shing is c/o 7/F, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong.

Item 2 (d)—(e). During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors), or has been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

Item 2 (f). Li Ka Shing, a natural person, is a permanent resident of the Hong Kong Special Administrative Region, People’s Republic of China. Each of Mayspin, Prime Tech, Apex, and Alpha is a corporation formed under the laws of the British Virgin Islands.

The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 3, as applicable.

August 2024 Transaction

On August 20, 2024, Prime Tech and Alpha entered into a securities purchase agreement (the “August 2024 Purchase Agreement”) with Brilliant Dynasty Limited, a British Virgin Islands corporation (“Brilliant Dynasty”), to sell all of the share capital of Champion River Ventures Limited, a British Virgin Islands corporation (“Champion River”), Winsave Resources Limited, a British Virgin Islands corporation (“Winsave”), and Radiant Treasure Limited, a British Virgin Islands corporation (“Radiant”) to Brilliant Dynasty, for an aggregate consideration of $32,058,489.15 (the “August 2024 Transaction”). At time of entry into the August 2024 Purchase Agreement, Prime Tech owned all of the share capital of Champion River and Alpha owned all of the share capital of Winsave and Radiant. At the time of entry into the August 2024 Purchase Agreement, Champion, Winsave and Radiant beneficially owned 7,940,937, 3,088,433 and 379,345 Shares, respectively, and by virtue of the August 2024 Transaction, Brilliant Dynasty will indirectly beneficially own the Shares held by Champion River, Winsave and Radiant.

September 2023 Transaction

On September 6, 2023, Alpha acquired all of the share capital of Winsave and Radiant from Li Ka Shing (Global) Foundation, a Cayman Islands company limited by guarantee (“LKSGF”). Winsave and Radiant beneficially own 3,088,433 Shares and 379,345 Shares, respectively. Alpha acquired Winsave for $1 and the assumption of a loan in the principal amount of $13,048,504.47 from LKSGF in favor of Winsave. Alpha acquired Radiant for $1 and the assumption of a loan in the principal amount of $1,672,688.07 from LKSGF in favor of Radiant.

September 2022 Securities Purchase Agreement

On September 30, 2022, Pioneer Step Holdings Limited, Champion River and Robert Fried IRA (each a “September 2022 Purchaser” and together, the “September 2022 Purchasers”) entered into a Securities Purchase Agreement with the Issuer (the “September 2022 Purchase Agreement”). Pursuant to the September 2022 Purchase Agreement, the Issuer agreed to issue and sell to the September 2022 Purchasers an aggregate of approximately $3.1 million of Common Stock (2,480,000 Shares) at a purchase price of $1.25 per share (the “September 2022 Transaction”). Champion River, in its capacity as a September 2022 Purchaser, has agreed to purchase 1,440,000 Shares in the September 2022 Transaction. The September 2022 Transaction closed on October 7, 2022.

May 2022 Joint Venture Agreement and Subsequent Termination

On May 19, 2022, the Issuer entered into an agreement (the “May 2022 Joint Venture Agreement”) for the formation of a joint venture (the “JV”) among Crystal Lake Developments Limited (“Crystal Lake”), Pioneer Idea Holdings Limited (“Pioneer Idea”), and Hong Kong Taikuk (China) Group Ltd (“Taikuk”). The purpose of the JV will be to commercialize Tru Niagen^® and other products containing nicotinamide riboside to be developed by the Issuer in the ordinary course (the “Products”) in Mainland China and its territories, excluding Hong Kong, Macau and Taiwan (the “Territory”). At the closing of the formation of the JV (the “Closing”) the Issuer will license to the JV certain inventions and trademarks relating to the Products and will exclusively own any invention developed by the JV that incorporates such intellectual property. The May 2022 Joint Venture Agreement will have an initial term of 20 years, unless earlier terminated. The Closing is subject to certain customary closing conditions and is expected by the end of the third quarter of 2022.

Crystal Lake, a company incorporated under the laws of the British Virgin Islands, is indirectly wholly-owned by Li Ka Shing.

Crystal Lake, Pioneer Idea and Taikuk have each agreed to contribute $1.8 million, $1.2 million and $1.0 million, respectively into the JV. Following the closing, each of the parties will hold the following interest in the JV: the Issuer (71%), Ciystal Lake (10.8%), Pioneer Idea (7.2%) and Taikuk (a 11% non-voting interest). The Issuer will have the right to elect three of the five directors in the JV, and Pioneer Idea, has the right to elect the other two directors, with each director having one vote with the exception of certain material corporate actions which will require unanimous approval of the board of the JV.

Prior to being able to commercialize the Products in the Territory, the JV will have to obtain all applicable regulatory approvals, including “Blue Hat” or health food registration with the PRC State Administration for Market Regulation for Products in the name of the Issuer or its designee (collectively, the “Blue Hat Registration”).

In addition, at the Closing the Issuer will enter into a distribution agreement with China National Pharmaceutical Group Co., Ltd. (“Sinopharm”) relating to the commercialization of the Products in the Territory on Sinopharm’s cross-border platform (the “Cross Border Agreement”) and the JV will enter into a distribution agreement with Sinopharm relating to the commercialization of the Products in the Territory. Upon Blue Hat Registration being obtained, the business of the JV will be to market, sell and distribute the Products in the Territory. Upon completion of the Blue Hat Registration, the parties intend that the Cross Border Agreement will be assigned to the JV.

On September 30, 2022 the Issuer entered into a Termination Agreement (the “Termination and Release Agreement”) among the Issuer, Crystal Lake, Pioneer Idea and Taikuk for the purpose of terminating the May 2022 Joint Venture Agreement. Each of the parties to the Termination and Release Agreement irrevocably and unconditionally released all other parties for any obligations under the May 2022 Joint Venture Agreement and releases all claims of action under the May 2022 Joint Venture Agreement.

The foregoing descriptions of the May 2022 Joint Venture Agreement and Termination and Release Agreement are not complete and are qualified in their entirety by reference to the full text of the May 2022 Joint Venture Agreement and Termination and Release Agreement, which are incorporated by reference into this Schedule 13D pursuant to Exhibit 99.7 and 99.10 of Item 7 hereof.

November 2017 Securities Purchase Agreement

On November 3, 2017, Champion River and certain other purchasers named therein (each a “November 2017 Purchaser” and together, the “November 2017 Purchasers”) entered into a Securities Purchase Agreement with the Issuer (the “November 2017 Purchase Agreement”). Pursuant to the November 2017 Purchase Agreement, the Issuer agreed to issue and sell to the November 2017 Purchasers an aggregate of approximately $23 million of Common Stock (5,609,755 Shares) at a purchase price of $4.10 per share (the “November 2017 Transaction”). Champion River, in its capacity as a November 2017 Purchaser, has agreed to purchase 731,707 Shares in the November 2017 Transaction. The November 2017 Transaction closed on November 17, 2017, at which closing the Issuer issued 731,707 Shares to Champion River and 4,878,048 Shares to the other November 2017 Purchasers.

April 2017 Securities Purchase Agreement

On April 26, 2017, Champion River and Pioneer Step Holdings Limited (“Pioneer Step”, each an “April 2017 Purchaser” and together, the “April 2017 Purchasers”) entered into a Securities Purchase Agreement with the Issuer (the “April 2017 Purchase Agreement”). Pursuant to the April 2017 Purchase Agreement, the Issuer agreed to sell and issue to the April 2017 Purchasers an aggregate of up to $25 million of its Common Stock at a purchase price of $2.60 per share in three tranches of approximately $3.5 million, $16.4 million and $5.1 million, respectively. The first tranche (the “First Tranche”) closed on April 27, 2017, at which closing the Issuer issued 807,692 Shares to Champion River and 538,462 Shares to the other April 2017 Purchaser. Pursuant to the First Amendment to Securities Purchase Agreement, dated May 24, 2017 (the “First Amendment”), by and among the Issuer and the April 2017 Purchasers, the second tranche (the “Second Tranche”) closed on May 24, 2017, at which closing the Issuer issued 3,782,288 Shares to Champion River and 2,521,526 Shares to the other April 2017 Purchaser. Pursuant to the First Amendment, following approval by the Issuer’s stockholders, the third tranche (the “Third Tranche”) closed on August 18, 2017, at which closing the Issuer issued 1,179,250 Shares to Champion River and 786,167 Shares to the other April 2017 Purchaser.

Upon completion of the Second Tranche, the April 2017 Purchase Agreement required that the Issuer’s Board of Directors (the “Board”) increase the number of authorized directors so as to create two vacant seats on the Board, which vacancies were to be filled on a date following the Issuer’s 2017 Annual Meeting of Stockholders by one designee selected by each of the April 2017 Purchasers (the “Purchaser Designees”). As such, Champion River exercised its right to designate for appointment an individual to fill one of the two vacancies on the Issuer’s Board.

In addition, from and after the date of the April 2017 Purchase Agreement, upon prior written request thereof by any April 2017 Purchaser, the Issuer shall use reasonable efforts to enter into one or more voting agreements with one or more of the April 2017 Purchasers and such other substantial holders of Common Stock as reasonably requested by such April 2017 Purchaser(s) and agreed to by the Issuer in respect of the election of the Purchaser Designees.

September 2022 Registration Rights Agreement

Simultaneously with the execution of the September 2022 Purchase Agreement, the Issuer, Pioneer Step, Champion River and Robert Fried IRA entered into a Registration Rights Agreement, dated as of September 30, 2022 (the “September 2022 Registration Rights Agreement”) with respect to the Shares acquired under the September 2022 Purchase Agreement. The September 2022 Registration Rights Agreement grants Pioneer Step, Champion River and Robert Fried customary shelf and piggyback registration rights.

November 2017 Registration Rights Agreement

Simultaneously with the execution of the November 2017 Purchase Agreement, the Issuer, Champion River and the other November 2017 Purchasers entered into a Registration Rights Agreement, dated November 3, 2017 (the “November 2017 Registration Rights Agreement”) with respect to the Shares acquired under the November 2017 Purchase Agreement. The November 2017 Registration Rights Agreement grants Champion River and the other November 2017 Purchasers customary shelf and piggyback registration rights.

April 2017 Registration Rights Agreement

At the closing of the First Tranche, the April 2017 Purchase Agreement required that the Issuer and the April 2017 Purchasers promptly enter into a Registration Rights Agreement in form and substance reasonably acceptable to the April 2017 Purchasers (the “April 2017 Registration Rights Agreement”) with respect to the Shares acquired under the April 2017 Purchase Agreement. The Issuer and the April 2017 Purchasers entered into the April 2017 Registration Rights Agreement on April 29, 2017. The April 2017 Registration Rights Agreement grants the April 2017 Purchasers customary shelf and piggyback registration rights.

The foregoing descriptions of the August 2024 Purchase Agreement, the September 2022 Purchase Agreement, the May 2022 Joint Venture Agreement, the Termination and Release Agreement, the November 2017 Purchase Agreement, the April 2017 Purchase Agreement, the September 2022 Registration Rights Agreement, the November 2017 Registration Rights Agreement, the April 2017 Registration Rights Agreement, and the First Amendment are not complete and are qualified in their entirety by reference to the full text of such agreements, which are incorporated by reference into this Schedule 13D pursuant to Exhibits 99.2—99.11 of Item 7 hereof.

Champion River and Alpha acquired the Shares pursuant to the above-described transactions as investments in its ordinary course of business.

In connection with the foregoing, and as may be appropriate from time to time, each of the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to its investment in the Issuer, including, without limitation: (a) the acquisition or disposition by the Reporting Persons of Shares, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) other material changes in the Issuer’s business or corporate structure; (g) changes in the Issuer’s articles of incorporation or bylaws or other actions that may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer’s securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12 of the Exchange Act; or (j) any action similar to those enumerated above.

Except as described in Item 6 and this Item 4 and any plans or proposals that may from time to time be discussed or considered by the directors of the Issuer, including the Purchaser Designee, in his fiduciary capacity as a director of the Issuer, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of this paragraph.

The Reporting Persons reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional Shares, dispose of some or all of the Shares, in each case in open market or private transactions, block sales or otherwise, and review or reconsider their position, change their purpose, take other actions (including actions that could involve one or more of the types of transactions or have one or more of the results described in clauses (a) through (j) of the foregoing paragraph of this Item 4) or formulate and implement plans or proposals with respect to any of the foregoing. Except as set forth in this Schedule 13D, no contract, arrangement, relationship or understanding (either oral or written) exists with respect to the Reporting Person as to the acquisition, disposition, voting or holding of Shares.

The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s stock in particular, as well as other developments.

(a) and (b) As of August 20, 2024, each of Li Ka Shing, Mayspin, Prime Tech, Apex and Alpha ceased to beneficially own, and ceased to have any voting or dispositive power over, any Shares.

(c) Information with respect to all transactions in the Shares beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 4 and incorporated herein by reference.

(d) Not applicable.

(e) As a result of the August 2024 Transaction described herein, each of Li Ka Shing, Mayspin, Prime Tech, Apex and Alpha ceased to be the beneficial owner of more than five percent of the Shares. The filing of this Amendment No. 9 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 6. Except as referenced above or described in Item 4 hereof, there are no contracts, arrangements, understandings or relationships among the Reporting Persons or between such Reporting Persons and any other person with respect to any securities of the Issuer.

Exhibit 99.1 Joint Filing Agreement as required by Rule 13d-1 (k)(l) under the Securities Exchange Act of 1934, as amended.

Exhibit 99.2 Securities Purchase Agreement, dated as of November 3, 2017, by and between ChromaDex Corporation, Champion River Ventures Limited, and certain other purchasers named therein (incorporated herein by reference to Exhibit 99.1 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 6, 2017).

Exhibit 99.3 Securities Purchase Agreement, dated as of April 26, 2017, by and between ChromaDex Corporation, Champion River Ventures Limited, and Pioneer Step Holdings Limited (incorporated herein by reference to Exhibit 99.1 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 27, 2017).

Exhibit 99.4 Registration Rights Agreement, dated as of November 3, 2017, by and between ChromaDex Corporation, Champion River Ventures Limited, and certain other purchasers named therein (incorporated herein by reference to Exhibit 99.2 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 6, 2017).

Exhibit 99.5 Registration Rights Agreement, dated as of April 29, 2017, by and between ChromaDex Corporation, Champion River Ventures Limited, and Pioneer Step Holdings Limited (incorporated herein by reference to Exhibit 99.1 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 2, 2017).

Exhibit 99.6 First Amendment to Securities Purchase Agreement, dated as of May 24, 2017, by and between ChromaDex Corporation, Champion River Ventures Limited, and Pioneer Step Holdings Limited (incorporated herein by reference to Exhibit 99.1 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 25, 2017).

Exhibit 99.7 Joint Venture Agreement, dated as of May 19, 2022, by and between ChromaDex Corporation, Crystal Lake Developments Limited, Pioneer Idea Holdings Limited and Hong Kong Taikuk (China) Group Ltd (incorporated herein by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 19, 2022).

Exhibit 99.8 Securities Purchase Agreement, dated as of September 30, 2022, by and between ChromaDex Corporation, Pioneer Step Holdings Limited, Champion River Ventures Limited and Robert Fried IRA (incorporated herein by reference to Exhibit 10.2 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 3, 2022).

Exhibit 99.9 Registration Rights Agreement, dated as of September 30, 2022, by and between ChromaDex Corporation, Pioneer Step Holdings Limited, Champion River Ventures Limited and Robert Fried IRA (incorporated herein by reference to Exhibit 10.3 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 3, 2022).

Exhibit 99.10 Termination Agreement, dated as of September 30, 2022, by and between ChromaDex Corporation, Crystal Lake Developments Limited, Pioneer Idea Holdings Limited, and Hong Kong Taikuk (China) Group Ltd (incorporated herein by reference to Exhibit 10.4 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 3, 2022).

Exhibit 99.11 Securities Purchase Agreement, dated as of August 20, 2024, by and between Prime Tech Global Limited, Alpha Mount International Limited and Brilliant Dynasty Limited.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: August 20, 2024

EXHIBIT INDEX

Exhibit 99.1

Joint Filing Agreement

The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of August 20, 2024.

Exhibit 99.11

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made on 20 August, 2024

BY AND AMONG:

The Sellers and the Purchaser are “Parties” (and each a “Party”) under this Agreement.

WHEREAS:

-1-

NOW THEREFORE, in consideration of the foregoing recitals, the mutual promises hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

(i) Such Seller is the sole legal and beneficial owner of the Sale Share of the Sale Company set forth in Schedule A next to such Seller’s name, free and clear of any liens, encumbrances, claims or restrictions of any kind, other than applicable securities laws, and such Seller has full power, right and authority to transfer such Sale Share to the Purchaser.

(ii) Such Sale Share constitutes all of the issued and outstanding share capital of the applicable Sale Company as set forth in Schedule A.

-2-

(iii) Such Sale Company, in turn, is the sole legal and beneficial owner of the ChromaDex Shares as set forth in Schedule B, free and clear of any liens, encumbrances, claims or restrictions of any kind, other than applicable securities laws.

(iv) Such Seller is the sole legal and beneficial owner of all and any rights in respect of the Shareholder Loan set forth in Schedule A next to such Seller’s name, free and clear of any liens, encumbrances, claims or restrictions of any kind and such Seller has full power, right and authority to sell and assign the full rights in respect of such Shareholder Loan to the Purchaser;

(v) Such Shareholder Loan represents the entire amount due and owing by the applicable Sale Company to the applicable Seller as set forth in Schedule A.

(vi) Since the date of its incorporation, such Sale Company has not conducted any business, or owned any assets, other than (i) holding the ChromaDex Shares and (ii) carrying out other activities incidental to its incorporation and the maintenance of its corporate existence. Such Sale Company does not have any debt or obligation of any nature, other than the Shareholder Loans and ordinary course expenses required for the incorporation and maintenance of the Sale Company.

-3-

[Signature Page Follows]

-4-

IN WITNESS WHEREOF, the parties hereto have executed this Securities Purchase Agreement as of the day and year first set forth above.

Signature Page to Securities Purchase Agreement

Schedule A

Sale Share

Shareholder Loan to be Assigned

Schedule B

Schedule C

Closing Deliveries

Part I. Sellers’ Deliveries

On the Closing Date, the Sellers shall deliver, or cause to be delivered, to the Purchaser each of the following items:

Part II. Purchaser’s Deliveries

On the Closing Date, the Purchaser shall deliver, or cause to be delivered, to Sellers the following items: